Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

Simulations Plus Inc (NASDAQ:SLP) is among the best medical AI stocks to buy now. On March 26, Simulations Plus announced ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Image source: Getty Images. Simulations Plus reported a 6% revenue decline in the fourth quarter to $17.5 million, with sales sinking across software and services. That revenue was slightly ahead of ...

Simulations Plus (NASDAQ:SLP) reports strong quarterly results as Nasdaq Index tracks tech healthcare software activity.

Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety The team at Simulations Plus will use the ...

Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago. These ...

Simulations Plus Inc. SLP reported better-than-expected results for its second quarter of fiscal 2026 on Thursday, while ...

Simulations Plus (NASDAQ:SLP) reported second-quarter fiscal 2026 revenue of $24.3 million, exceeding the top-line guidance management provided last quarter, as the company delivered growth in both ...